885270-83-7

Basic information

• Product Name: (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER;tert-butyl (2-aMinophenyl)(Methyl)carbaMate
• CAS NO: 885270-83-7
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Mol File: 885270-83-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(885270-83-7)
• EPA Substance Registry System: (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(885270-83-7)

Safety Data

• Hazardous Substances Data: 885270-83-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of a wide range of pharmaceuticals. It plays a crucial role in the production of anti-inflammatory drugs, antibiotics, and antiviral medications due to its ability to act as a nucleophile and as a protecting group for amine functionalities in organic reactions.
Used in Organic Synthesis:
In the field of organic synthesis, (2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is used as a nucleophilic agent for various chemical reactions. Its reactivity allows it to participate in a multitude of organic transformations, contributing to the synthesis of complex organic molecules and compounds.
Used in Agrochemical Research:
(2-AMINO-PHENYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is also utilized in agrochemical research as a building block for the development of new agrochemicals. Its versatility in organic synthesis makes it a valuable component in the creation of novel compounds with potential applications in agriculture and pest control.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 54614-93-6 (2-nitro-phenyl)-carbamic acid tert-butyl ester 
• 88-74-4 2-nitro-aniline 
• 612-28-2 2-nitro-N-methylaniline 

Downstream Products

• 1037793-64-8 C₁₈H₂₁N₃O₆S 
• 1037793-72-8 C₁₄H₁₅N₃O₄S 
• 1037793-76-2 C₁₅H₁₄ClN₃O₅S 
• 1037793-68-2 C₁₉H₂₃N₃O₆S 
• 1037793-88-6 C₂₇H₃₈N₆O₆ 
• 1037793-92-2 C₂₈H₃₇ClN₆O₇ 
• 1037793-84-2 C₃₃H₄₁N₇O₁₀S 
• 1037793-99-9 C₅₄H₆₁ClN₈O₁₁ 

Relevant articles and documents

BENZOTHIADIAZINE COMPOUNDS

The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.

CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.